Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Sells $108,860.97 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $9.51, for a total value of $108,860.97. Following the completion of the transaction, the director now directly owns 7,177,116 shares in the company, valued at $68,254,373.16. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, June 11th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.45, for a total value of $96,727.15.
• On Tuesday, May 28th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.17, for a total value of $104,968.99.
• On Tuesday, April 30th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.95, for a total value of $91,003.65.
• On Tuesday, April 16th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.66, for a total value of $87,684.02.
• On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.82, for a total value of $100,962.54.

Recursion Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ RXRX opened at $7.50 on Friday. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.97 and a 12 month high of $16.75. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -4.69 and a beta of 0.86. The business has a fifty day simple moving average of $8.84 and a 200-day simple moving average of $9.94.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The business had revenue of $13.80 million during the quarter, compared to the consensus estimate of $11.10 million. During the same period in the prior year, the business posted ($0.34) earnings per share. Recursion Pharmaceuticals’s revenue was up 14.0% compared to the same quarter last year. As a group, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.6 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, June 25th. KeyCorp upped their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Monday, March 4th.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently bought and sold shares of RXRX. Benjamin F. Edwards & Company Inc. purchased a new stake in Recursion Pharmaceuticals in the 1st quarter worth about $26,000. National Bank of Canada FI lifted its stake in Recursion Pharmaceuticals by 90.9% in the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after acquiring an additional 1,500 shares in the last quarter. First Horizon Advisors Inc. purchased a new stake in Recursion Pharmaceuticals in the 4th quarter worth about $47,000. QRG Capital Management Inc. purchased a new stake in Recursion Pharmaceuticals in the 3rd quarter worth about $86,000. Finally, Oxford Wealth Group LLC purchased a new stake in Recursion Pharmaceuticals in the 1st quarter worth about $106,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.